title: Selective degeneration of septal and hippocampal GABAergic neurons in a mouse model of amyloidosis and tauopathy.
abstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by brain accumulation of amyloid-β peptide and neurofibrillary tangles, which are believed to initiate a pathological cascade that results in progressive impairment of cognitive functions and eventual neuronal death. To obtain a mouse model displaying the typical AD histopathology of amyloidosis and tauopathy, we generated a triple-transgenic mouse line (TauPS2APP) by overexpressing human mutations of the amyloid precursor protein, presenilin2 and tau genes. Stereological analysis of TauPS2APP mice revealed significant neurodegeneration of GABAergic septo-hippocampal projection neurons as well as their target cells, the GABAergic hippocampal interneurons. In contrast, the cholinergic medial septum neurons remained unaffected. Moreover, the degeneration of hippocampal GABAergic interneurons was dependent on the hippocampal subfield and interneuronal subtype investigated, whereby the dentate gyrus and the NPY-positive interneurons, respectively, were most strongly affected. Neurodegeneration was also accompanied by a change in the mRNA expression of markers for inhibitory interneurons. In line with the loss of inhibitory neurons, we observed functional changes in TauPS2APP mice relative to WT mice, with strongly enhanced long-term potentiation in the medial-perforant pathway input to the dentate gyrus, and stereotypic hyperactivity. Our data indicate that inhibitory neurons are the targets of neurodegeneration in a mouse model of amyloidosis and tauopathy, thus pointing to a possible role of the inhibitory network in the pathophysiological and functional cascade of Alzheimer's disease.
authors.affiliation: Department of Neuroanatomy, University of Freiburg, Germany.
authors.forename: Desirée
authors.initials: D
authors.lastname: Loreth
authors.forename: Laurence
authors.initials: L
authors.lastname: Ozmen
authors.forename: Florent G
authors.initials: FG
authors.lastname: Revel
authors.forename: Frédéric
authors.initials: F
authors.lastname: Knoflach
authors.forename: Philine
authors.initials: P
authors.lastname: Wetzel
authors.forename: Michael
authors.initials: M
authors.lastname: Frotscher
authors.forename: Friedrich
authors.initials: F
authors.lastname: Metzger
authors.forename: Oliver
authors.initials: O
authors.lastname: Kretz
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D000686:Amyloidosis / Q000473:pathology; D000818:Animals; D059329:Cholinergic Neurons / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D059330:GABAergic Neurons / Q000378:metabolism* / Q000473:pathology; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology; D007395:Interneurons / Q000378:metabolism* / Q000473:pathology; D017774:Long-Term Potentiation; D051379:Mice; D008822:Mice, Transgenic; D009478:Neuropeptide Y / Q000378:metabolism; D053766:Presenilin-2 / Q000235:genetics; D012686:Septal Nuclei / Q000378:metabolism* / Q000473:pathology; D024801:Tauopathies / Q000473:pathology; D016875:tau Proteins / Q000235:genetics
chemical_list: D009478:Neuropeptide Y; D053766:Presenilin-2; D016875:tau Proteins